Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis
ChemomAb Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company, has published a research article in JCI Insight that highlights the important role of CCL24 in primary sclerosing cholangitis (PSC). The article includes extensive data showing that Chemomab's CCL24-neutralizing antibody, CM-101, can interrupt the fibro-inflammatory processes that lead to PSC.
Primary sclerosing cholangitis is a rare disease of the bile ducts that currently has no FDA-approved treatments and often leads to fatal outcomes. The publication describes how elevated levels of CCL24 drive the fibrotic and inflammatory disease processes seen in PSC. It also presents preclinical studies demonstrating the effectiveness of CM-101 in interrupting these processes and potentially improving patient outcomes.
CM-101 is currently undergoing Phase 2 trials for the treatment of PSC. The